This is a preview of subscription content, log in via an institution to check access.
Reference
Sorensen S, et al. Budgetary impact on a u.s. Health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. Journal of Managed Care Pharmacy 19: 799-808, No. 9, Nov 2013. Available from: URL: http://dx.doi.org/2013(19)9:799-808 [pii]
Rights and permissions
About this article
Cite this article
Abiraterone should not be resisted by health plans. PharmacoEcon Outcomes News 691, 4 (2013). https://doi.org/10.1007/s40274-013-0855-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0855-y